Cero Therapeutics Holdings Inc. has entered into a new purchase agreement with an institutional investor, allowing the company to issue and sell up to approximately $14.6 million of its common stock. This agreement is a continuation of the company's previous equity line arrangements, which have raised proceeds through the sale of shares under agreements dated February 2024, November 2024, and July 2025. Under the new agreement, Cero Therapeutics may direct the investor to purchase shares at specified times and prices, subject to certain limitations, with each purchase not exceeding 10,000 shares or $100,000 per transaction. The sales are being made in a private placement without registration under the Securities Act.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-116971), on December 02, 2025, and is solely responsible for the information contained therein.
Comments